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ABSTRACT
Purpose: To compare technique efficacy and safety of laser ablation (LA) and radiofrequency ablation
(RFA) in treatment of benign thyroid nodules.
Materials and methods: Institutional review board approval was obtained, and patients’ consent was
waived. 601 nodules were treated from May 2009 to December 2014 at eight centres, 449 (309
females, age 57±14 years) with LA and 152 (107 females, age 57±14 years) with RFA. A matched
cohort composed of 138 patients from each group was selected after adjustment with propensity score
matching. Factors influencing volume reduction at 6 and 12months and complications were evaluated.
Results: No significant differences were observed in the baseline characteristics between groups after
propensity score matching adjustment. Mean nodule reduction at 6 and 12months was 67±19% vs.
57±21% (p< 0.001) 70±19% vs. 62±22% (p ¼ 0.001) in LA group and in RFA group, respect-
ively. Nodules with volume>30mL had significantly higher percentage volume reduction at 6 and
12months (69±19 vs. 50±21, p¼ 0.001) and (73±18 vs. 54±23 8, p¼ 0.001) in the LA group
than in the RFA group, respectively. In both groups, operator’s skills affected the results. Major compli-
cations occurred in 4 cases in each group (p¼ 0.116)
Conclusions: LA and RFA showed nearly similar outcome but LA was slightly more effective than RFA
in large nodules. Operator’s skills could be crucial in determining the extent of nodule volume reduc-
tion regardless of the used technique.
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Introduction
Over the last years, image-guided minimally-invasive techni-
ques have been proposed to treat clinically relevant benign
thyroid nodules (BTNs) [1,2]. Ultrasound-guided (US-g) ther-
mal ablation with laser or radiofrequency energy is increas-
ingly being used for non-surgical management of
symptomatic non-functioning thyroid nodules that are
benign at cytological assessment [3]. Due to their debulking
efficacy, substantial safety and low-cost as outpatient proce-
dures, both laser ablation (LA) and radiofrequency ablation
(RFA) are currently used in several thyroid referral centres.
Microwave ablation (MWA) technique, on the other hand,
represents an emerging but still not thoroughly assessed and
well established ablative method for BNTs [4–6].
Numerous uncontrolled and prospective randomised con-
trolled trials with different treatment algorithms have con-
firmed the clinical effectiveness and safety of LA [7–19] and
of RFA in both solid thyroid nodules and in lesions with vari-
able fluid component [20–27]. However, the reported series
of LA usually included patients with larger thyroid nodules
and the series of RFA included patients with a higher cyst
component [2]. Thus, the results are difficult to be compared
[28]. To date, only one review including meta-analysis [29]
and a more recent paper on a small case series [30] have
reported direct comparisons between the two techniques
with contradictory conclusions. While the first study con-
cludes that RFA is superior to LA, the second highlights a
substantial equivalence of the two techniques when per-
formed by operators with the same expertise. Thus, pending
prospective comparative studies, we retrospectively com-
pared LA and RFA outcomes in the treatment of benign thy-
roid nodules in a large cohort of patients treated at different
centres in Italy. In order to minimise the effect of potential
confounders or selection bias, patients of each group were
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matched by applying the one-to-one propensity score match-
ing [31,32]. The aim of our study was to compare in real clin-
ical practice the efficacy and safety of LA and RFA in the
treatment of benign thyroid nodules.
Methods
Patients
The institutional review board of each participating centre
approved this retrospective study and waived the require-
ment for informed consent. All patients undergoing percu-
taneous thermal ablation for symptomatic BTNs from May
2009 to December 2014 at eight thyroid referral centres
were retrospectively considered for the study. Four of these
centres had specific expertise in RF technique while four of
them used laser technology. Then, four centres have only
used RFA technique and four laser technology. In four
centres the procedures were performed by endocrinologists,
in three by interventional radiologists, and in one by sur-
geons. The patients had refused surgery or had poor surgi-
cal indications because of age, cardiovascular risk,
respiratory failure or because they were not eligible for gen-
eral anaesthesia. No patient had undergone ethanol sclero-
therapy or other percutaneous minimally invasive therapies.
Inclusion criteria were as follows: solid nodule (uniformly
compact or nearly completely solid, with a liquid compo-
nent not exceeding 30%); evidence at ultrasound examin-
ation of a single or of a dominant nodule, clearly
detectable in a multinodular goitre; serum TSH and thyroid
hormones within normal range; benign cytological examin-
ation (class II of the Bethesda classification system) [33]
assessed by two separate FNAs; and presence of either local
pressure symptoms or cosmetic concern. Patients were
excluded from the treatment in case of suspicious or cyto-
logically proven malignancy, altered serum TSH and thyroid
hormones or coagulation disorders.
Preoperative patient management
A general consensus among centres for clinical, ultrasound
and laboratory assessment was based on the international
guidelines criteria [34,35]. Thyroid sonographic evaluation
was conducted in all centres by means of a commercially
available US scanner, equipped with a 7.5–13.0MHz linear
transducer. The nodule volume was calculated with the
ellipsoid formula (V¼ lengthwidthdepth 0.525). Serum
TSH, FT4 and other laboratory controls were determined with
commercially available immunoradiometric assay kits. Routine
coagulation tests were performed before the procedure and
included INR and platelet count. All centres operated accord-
ing to the guidelines used for interventional procedures in
other organs, such as liver, kidney or lung [36,37]. Only one
session of treatment was scheduled for each nodule.
Technique
The treatment procedures followed those previously applied
and published elsewhere [7]. Briefly, in the case of laser
technique, the number of 21 gauge (G) applicators (up to
four) to be inserted is based on nodule size. Under US-g the
introducer needles, and subsequently the optic fibres, are
inserted into the target thyroid nodule along its longest axis.
Each treatment is performed using diode lasers with a fixed-
power protocol (3W). Each illumination time ranges from a
minimum of 400 s to a maximum of 600 s to achieve a total
energy delivery between 1200 and 1800 Joules per fibre.
Depending on the size of the nodule, one to three consecu-
tive illuminations are performed with a pullback technique
during the same treatment session.
For the radiofrequency technique, the procedure is
based on the moving-shot technique as described else-
where [21]. Under US-g electrode-needles with a calibre
ranging from 17G to 19G are inserted into the thyroid
nodule along its short axis by using a trans-isthmic
approach. Different zones of the lesion were ablated
sequentially by moving the position of the electrode tip.
The electrode was initially positioned in the deepest part of
the nodule and was moved into the central and finally the
superficial areas of the lesion. During the manoeuvre, the
output power ranges from 40 to 80W, and the exposure
time was calculated mainly on the appearance of a transi-
ent hyperechoic area in each of the different zones under-
going ablation [26,27]. The number of insertions depends
on the nodule size.
In different centres, the RFA procedures were per-
formed by two endocrinologists with 4 and 6 years of
experience, respectively, and by two interventional radiol-
ogists with 3 and 5 years of experience in the moving-
shot technique, respectively. Laser procedures were per-
formed by three endocrinologists with 1, 6 and 10 years
of experience, respectively, and by a surgeon with 7 years
of experience.
Data analysis
The nodule population was classified, in agreement with the
available data in the literature [11,14,27], into three groups
according to the baseline volume. Nodules with initial
volume 13ml were defined as small, those between 13.1 to
30.0ml as medium, and those >30.0ml as large [38].
Preoperative characteristics, age, sex, ablation time, energy
deployed per nodule and results in terms of percentage vol-
ume reduction (PVR) at 6 and 12months in RFA and LA
groups were compared overall and according to the baseline
nodule volume. In each centre, operators performing the
ablation were involved in the assessment of the results and
data collection. Previous clinical evidence consistently dem-
onstrated that the major volume reduction of nodules occurs
within the first six months after treatment (with significant
improvement of local symptoms), followed by a minor reduc-
tion from the sixth to the twelfth month [2,39]. On the basis,
technical success was defined as a 50% volume reduction
at 6months after a single treatment session. Three treatment
variables were considered and correlated with a successful
outcome: baseline nodule volume, total ablation time
(from the initial targeting of applicator(s) into thyroid nodule
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to the final assessment after treatment) and total energy
delivered per treatment session. Finally, we compared major
and minor complications of the two treatment modalities,
classifying them according to the time of occurrence as intra-
procedural (during the thermal session), postprocedural
(within 24 h), periprocedural (within 30 days) and late compli-
cations [36,37].
To minimise the effect of potential confounders on selec-
tion bias, propensity scores were generated by using binary
logistic regression to estimate the probability that a patient
would undergo RFA instead of LA. Independent variables
that entered into the propensity model included sex, age
and baseline nodule volume.
Statistical analysis
Statistical analyses were performed using statistical software
(SPSS, version 22.0 for Windows; SPSS, Chicago, Ill). All data
were first analysed for normality of distribution using the
Kolmogorov–Smirnov test of normality. One-to-one matching
between the treatment groups was accomplished by using
the nearest-neighbour matching method [31,32,40]. Briefly,
the distribution of propensity scores was evaluated by treat-
ment group to examine for sufficient overlap among the
groups to ensure comparability. Continuous variables were
expressed as mean± SD, categorical variables displayed as
frequencies and the appropriate parametric (student t-test)
or non-parametric test (Mann–Whitney U-test or v2 test) was
used to assess significance of the differences between sub-
groups. A p value of less than 0.05 was considered statistic-
ally significant.
Results
Baseline characteristics of LA and RFA groups
Six hundred and one nodules in 601 euthyroid patients were
ablated percutaneously through US-g thermal therapy. Four
hundred and forty-nine (mean age 57± 14) underwent LA
while 152 (mean age, 57 ± 14) underwent RFA. The baseline
characteristics of all patients are shown in Table 1. A number
of cases treated in each centre are reported in Figure 1(A,B).
The mean total baseline volume of the nodules treated with
LA did not show statistically significant differences
(21.5 ± 16.5 vs. 24.6 ± 17.9ml, respectively; p¼ 0.065) com-
pared with nodules treated with RFA. Patients with baseline
nodule volume>30ml who underwent RFA were significantly
older (65 ± 14 vs. 58 ± 15 years, respectively; p¼ 0.028) than
those who underwent LA. The mean baseline nodule volume
in group of patients with nodules13ml was significantly
greater in patients who underwent RFA than in patients
who underwent LA (9.9 ± 2.9 vs. 7.4 ± 3.1ml, respectively;
p< 0.001) (Table 1).
Volume reduction according to baseline nodule volume
Mean nodule volume decreased from 21.5 ± 16.5 at baseline
to 8.7 ± 7.7 (p < 0.001) and to 8.0 ± 7.2ml (p< 0.001) at 6 and Ta
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12months, respectively, after treatment in patients who
underwent LA. Mean nodule volume decreased from
24.5 ± 17.9ml at baseline to 11.3 ± 10.7 (p< 0.001) and to
9.9 ± 9.5ml (p< 0.001) at 6 and 12months, respectively, after
treatment (p< 0.001) in patients who underwent RFA. There
were no statistically significant differences between the two
treatment groups.
Volume reduction in nodules >30ml at both 6 and
12months was significantly higher (p¼ 0.003 and p¼ 0.033,
respectively) in LA group (from mean 45.1 ± 16.6ml baseline
volume to 17.6 ± 9.8ml and to 16.0 ± 9.3ml, respectively)
than in RFA group (from mean 49.0 ± 20.3ml baseline vol-
ume to 24.6 ± 13.3ml and to 21.5 ± 11.5ml, respectively).
The total energy delivered per treatment/session was signifi-
cantly higher in nodules treated with RFA than in nodules
treated with LA (64.6 ± 58 vs. 5.8 ± 2.7 kJ, p¼ 0.001). There
was no statistically significant difference in ablation time
between the two techniques. All results are summarised in
Table 1.
Technical results
Although not statistically significant, the rate of technical suc-
cess was higher in LA- than in RFA-treated patients (75% vs.
69%; p¼ 0.197). The baseline volume was higher in PVR
50% group than in PVR <50% group (p¼ 0.006) in the
LA-treated while this finding was not observed in the RFA-
treated patients. Total energy delivered was higher in PVR
50% group than in PVR <50% group, both in LA-treated
patients (p¼ 0.033) and in RFA-treated patients (p¼ 0.010).
Finally, ablation time was longer in the PVR 50% than in
PVR <50% group, both in all study patients (p ¼ 0.001) and
in only RFA treated-patients (p ¼ 0.002). Table 2 summarises
all these data. Figure 1(A,B) shows the distribution of the
number of patients with a nodule volume reduction higher
or lower than 50% at 6months in the LA (panel A) and in
the RFA (panel B) groups according to the different centres/
operators. In both groups, operators with interventional train-
ing (surgeons or interventional radiologists) had the highest
rate of >50% volume reduction.
Figure 1. The figure shows the operator’s role in determining the extent of nodule volume reduction using laser light (A) or radiofrequency energy (B).
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Comparison of volume reduction rates between LA
group and RFA group after one-to-one propensity score
matching
We trimmed the sample by removing 325 patients (RFA,
n¼ 14; LA, n¼ 311) with non-overlapping propensity score
distribution. Therefore, adjusted comparisons by propensity
scores were based on data from 138 patients for each treat-
ment arm. Confounding factors were well matched between
the LA and RFA groups: mean age 57± 14 vs. 57 ± 13
(p¼ 0.932), baseline nodule volume 21.9 ± 13.3 vs. 21.5 ± 11.5
(p¼ 0.760), and female subjects 69% vs. 72% (p ¼ 0.572),
respectively. Therefore, after this matching the resulting two
patient groups had similar baseline characteristics. After
this adjustment, mean nodule reduction at 6 and 12months
was 67± 19% (mean volume 7.5 ± 6.6ml) vs. 57 ± 21%
(9.6 ± 7.5ml) (p< 0.001) and 70± 19% (6.6 ± 6.2ml) vs.
62± 22% (8.6 ± 7.8ml) (p¼ 0.001) in LA vs. RFA group.
Nodules with volume>30ml had significantly higher percent-
age volume reduction at 6 and 12months in the LA group
than in the RFA group (70 ± 19% vs. 62 ± 22, p¼ 0.001). No
difference in total ablation time was detected (17.7 ± 6.3 vs.
18.7 ± 13.6min (p¼ 0.436), while a lower release of energy in
the LA group compared to the RFA group was confirmed
(6.1 ± 2.7 vs. 61.6 ± 51.4kJ, respectively; p¼ 0.001) (Table 3).
According to the PVR50% response, the rate of volume
reduction was greater in LA than in RFA group (86% vs. 70%
and 92% vs. 78%) at 6 and 12months, respectively. In Figure
2, we report the mean nodule reduction at 6 and 12months
according to baseline nodule volume group in all patients
before (A) and after (B) propensity score adjustment. Again,
in both groups the propensity score-matching analysis
confirmed the operators’ role in determining a volumetric
reduction greater than 50% at six months.
Complications
No immediate or late changes in thyroid function were
observed. Thyroid-stimulating hormone, (TSH) free triiodo-
thyronine (FT3) and free thyroxine (FT4) serum levels
remained stable. No significant changes were observed in
anti-thyroglobulin (TgAb) and anti-thyroperoxidase (TPOAb)
antibodies titres during follow up, except for a single patient
with a large nodule who developed autoimmune hyperthy-
roidism six months after RF ablation. Table 4 reports the inci-
dence of major and minor complications and side effects in
both groups.
Discussion
Several case reports and prospective randomised trials have
established the clinical effectiveness of US-g thermal ablation
procedures for the management of symptomatic BTNs [39].
Presently, a still unresolved issue concerns the comparison of
the two mainly used techniques – laser and RF – in terms of
technique efficacy and safety in real clinical practice. One
recent systematic review tried to compare the results of RFA
and LA from the data of the published literature, and con-
cluded that RFA appears to be superior to LA in reducing
benign solid thyroid nodule volume [29]. However, in this
paper, the considered studies had very small number of
patients (range 10–21), papers regarding LA were all signifi-
cantly older than paper regarding RFA, and 6 out of 8
Table 2. Predictive factors for percentage volume reduction (PVR) at 6th month in all study patients and according to LA or RFA treatment before propensity
score matching.
All patients LA group RFA group
PVR <50%
(n¼ 161) 27%
PVR 50%
(n¼ 440) 73% p Value
PVR <50%
(n¼ 114) 25%
PVR 50%
(n¼ 335) 75% p Value
PVR <50%
(n¼ 47) 31%
PVR 50%
(n¼ 105) 69% p Value
Age (yrs) 55 ± 14 57 ± 14 0.193 55 ± 14 57 ± 14 0.087 58 ± 16 57 ± 13 0.871
Female (%) 74 68 0.160 75 67 0.140 72 70 0.815
Baseline volume 21.4 ± 17,2 22.6 ± 16.8 0.412 18.3 ± 13.5 22.6 ± 17.3 0.006 28.8 ± 22.3 22.7 ± 15.3 0.095
Total energy (kJ)a 17.4 ± 33.8 21.8 ± 40.4 0.177 5.4 ± 2.6 6.0 ± 2.7 0.033 47.1 ± 52.4 72.3 ± 59.1 0.010
Ablation time (min) 15.5 ± 9,7 18.5 ± 9,5 0.001 16.2 ± 6.7 17.4 ± 6.3 0.101 13.6 ± 14.5 21.9 ± 15.3 0.002
Values are reported as mean ± SD.
akJ: KiloJoules.
Table 3. Results in all study patients according to baseline nodule volume group after propensity score matching.
LA group nodule volume (ml) RFA group nodule volume (ml) p Value
13
(n¼ 34)
13.1–30
(n¼ 74)
>30
(n¼ 30)
Total
(n¼ 138)
13
(n¼ 34)
13.1–30
(n¼ 74)
>30
(n¼ 30)
Total
(n¼ 138)
13
(n¼ 68)
13.1–30
(n¼ 148)
>30
(n¼ 60)
Total
(n¼ 276)
Volume reduction at
6th month (%)
67 ± 22 65 ± 17 69 ± 19 67± 19 57 ± 25 59 ± 19 50 ± 21 57 ± 21 0.071 0.026 0.001 <0.001
Volume reduction at
12th month (%)
70 ± 22 69 ± 18 73 ± 18 70± 19 67 ± 24 63 ± 19 54 ± 23 62 ± 22 0.646 0.047 0.001 0.001
Total energy (kJ)a 4.0 ± 2.0 6.6 ± 2.2 7.1 ± 3.1 6.1 ± 2.7 44.8 ± 30.5 59.9 ± 41.0 88.0 ± 83.3 61.6 ± 51.4 <0.001 <0.001 <0.001 <0.001
Ablation time (min) 12.6 ± 4.8 18.9 ± 4.8 20.5 ± 7.3 17.7 ± 6.2 13.9 ± 8.1 18.2 ± 10.7 25.8 ± 21.8 18.7 ± 13.6 0.435 0.623 0.238 0.437
Values are reported as mean ± SD.
akJ: Kilojoules.
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considered papers on LA were performed by the same
author. A more recent paper compared results of LA and RFA
performed by the same equipe of operators, and found no
significant differences among the two techniques, suggesting
that the two techniques might be similarly effective when
performed by operators with the same expertise. However,
this study was based on a limited experience of a single
equipe of operators [30]. For this reason, our comparative
study was performed on a consecutive population of patients
treated in thyroid referral centres and its outcomes reflect
the clinical findings of the everyday activities of well-trained
operators working in this field. To our knowledge, this is the
first large retrospective cohort study to date which compares
safety and technique efficacy of RFA and LA in the percutan-
eous treatment of benign solid thyroid nodules by using pro-
pensity score matching with power analysis and statistically
simulating randomised controlled trials [31].
This study leads to some interesting considerations. The
first is that both percutaneous thermal ablation procedures
were highly effective in inducing a significant decrease in
thyroid nodule volume. Both techniques were equally effect-
ive in small and medium size nodules, while the laser tech-
nique showed a slightly greater efficacy than RFA in nodules
larger than 30ml (Table 1 and Figure 2(A,B)). Based on previ-
ous studies on thyroid tissue and in other organs [13,41–43],
this different outcome could be due to the simultaneous use
of multiple (up to four) laser sources in large nodules, with a
more homogeneous distribution of heat energy in the target
area and thus with greater treatment efficacy. Moreover, with
the trans-isthmic approach it might be more difficult to treat
the deeper part of large nodules, which can be conversely
easily reached by a direct puncture of the nodule on its long
axis. After adjustment by the propensity score matching, the
higher rate of PVR in the LA group for large thyroid nodules
was confirmed (as represented in Figure 2(B) and in Table 3).
Notably, both techniques produced a rather wide variability
in nodule volume reduction (Figure 3(A,B)). This results in a
relevant overlap between the two procedures. Although the
statistical analysis shows a significant difference between LA
and RFA, in clinical practice the different efficacy of the two
Figure 2. The figure shows the mean nodule reduction at 6months according to baseline nodule volume group in all patients before (A) and after (B) propensity
score adjustment. After propensity score-matching analysis, the higher rate of PVR in LA group in comparison with RFA group, appears confirmed in large nodules
(>30ml) thyroid nodules, appears clearly confirmed.
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techniques seems to be of minor importance. A randomised
controlled trial (RCT) could confirm this specific finding. To
this end, we are currently conducting an ongoing Phase III
trial and we are recruiting patients to prospectively assess
the effectiveness and safety of LA compared to RFA
(ClinicalTrials.gov identifier: NCT02714946) in order to avoid
the potentially confounding bias present in this retrospective
study.
A second and the most relevant finding, as shown in
Figure 1, is the role of the operator in determining the
efficacy and the extent of nodule volume reduction. The
influence of the operator experience on the treatment out-
come was confirmed, regardless of whether laser light or
radiofrequency energy was used. The proper targeting of
nodules in close proximity to vital structures such as neck
vessels, trachea and laryngeal nerve requires a good man-
ual skill in placing the devices correctly in an anatomical
region as small as the neck. This problem underscores the
importance of appropriate training and learning curve,
which should be longer for operators who are not confi-
dent with minimally invasive procedures. This issue should
be better clarified by a study addressed to the learning
curve of individual operators for thyroid minimally invasive
techniques.
Thirdly, we observed that to achieve a comparable vol-
ume reduction in small and medium size nodules, the oper-
ators used more energy (about ten times more) with the
radiofrequency technique than with laser technology
(Table 2 and Figure 2). This finding could be explained by
the different modalities of production and distribution of
thermal energy within the tissue to be ablated by means
of the two techniques. The last data, however, do not seem
to be relevant in clinical practice because they are inherent
to the technique used but do not cause the undesired
effects on thyroid tissue that are described in hepatic ther-
mal ablation [44–46].
The two procedures appeared both safe and well toler-
ated, with a similar complications rate (Table 4). The easiness
of use of techniques seems to be subjective and in most
cases is dependent on the clinical circumstances and on the
devices available in the institution where the operators work.
Finally, since costs are becoming more and more import-
ant in decision making, may be useful to consider the costs
of the two techniques. Taking into account the rental of gen-
erators in both techniques, the cost of a single laser applica-
tor is about U.S.$250 per session (in most cases two
applicators are needed) while the cost of an RFA electrode is
about U.S.$800 per session. Both treatments may be per-
formed on outpatients by an operator and a nurse. In both
procedures, the cost of dressings, including local anaesthetics
and pain-killers, is quite low.
Our study has some limitations. First, we used a retro-
spective approach; therefore, inherent selection bias was
unavoidable, even with the propensity score analysis.
Second, this was a multicentre study with only eight partici-
pating centres, even if each of them had a large volume of
percutaneous RFA or LA ablation. Moreover, operators were
involved in the results assessment and data collection, and
some possible bias should be taken into account. Therefore,
we believe that careful consideration is needed before gener-
alising our results to other settings.
In summary, this study confirms the efficacy and safety in
different clinical settings of US-g thermal ablation procedures
consistently with previous reports. RFA and LA techniques
seem to provide similar results, with a high success rate and
low risk of major complications. The only difference was
observed in the efficacy of LA in comparison with RFA in treat-
ment of large size nodules. This finding seems to be, at least in
part, due to the variable skill and experience of the operators.
Table 4. Major, minor complications and side effects in each group of 138 patients.
Type of complications
(SIR Class)a
Complications and side effects no. (%)b time of detection
Time to
recovery (days)
p
Intra-procedural
Immediate
post-procedural
(within 24 h)
Peri-procedural
(within 30 days)
Delayed (after
30 days)
LA RFA LA RFA LA RFA LA RFA LA RFA
Major
Voice changec (C) 4 (1.2) 3 (2.7) 28–84 2-permanentd NS
Hyperthyroidism (C) 1 (0.6) NS
Minor
Hematoma (B) 3 (0.9) 5 (4.5) 5–10 5–10 0.044
Side effects
Pain (A)
Mild 18 (5.5) 12 (10.9) NS
Moderate 4 (1.3)e 1–4 NS
Severe 2 (0.6)e 1 (0.9) 2 (0.6)f 1–3 1 NS
Vasovagal reaction (A) 4 (1.2) NS
Fever (37.5 C–38.5 C) (A) 6 (1.8) 1–4 NS
aSociety of Interventional Radiology (SIR) guidelines criteria; Minor complications: A: No therapy, no consequence; B: Nominal therapy, no consequence; includes
overnight admission for observation only. Major Complications: C: Require therapy, minor hospitalisation (<48 h); D: Require minor therapy, unplanned increase
in level of care, hospitalisation >48 h; E: Permanent adverse sequelae; F: Death.
bValue calculated per LA sessions.
cTransient or permanent cord paralysis.
dOne case with permanent stridor.
eWith discomfort.
fWith swelling.
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So the operator’s specific manual ability in ablative techniques
appears crucial, regardless of the chosen technique.
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